Patents by Inventor Masao Yoshida
Masao Yoshida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240258080Abstract: A focus ring according to the present disclosure includes a placement surface accommodating a substrate to be treated and facing a lower surface of the substrate to be treated, and a back surface located on an opposite side to the placement surface. An average value of a cutting level difference (R?c) representing a difference between a cutting level at a load-length ratio of 25% in a roughness curve and a cutting level at a load-length ratio of 75% in the roughness curve is greater in a supported portion of the back surface supported by one support member than in the placement surface.Type: ApplicationFiled: May 25, 2022Publication date: August 1, 2024Inventor: Masao YOSHIDA
-
Publication number: 20240082413Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: March 3, 2023Publication date: March 14, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi MASUDA, Hiroyuki NAITO, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Hideki MIYAZAKI, Yuji KASUYA, Koji MORITA, Yuki ABE, Yusuke OGITANI
-
Publication number: 20240026030Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La—(CH2)n2—C(?O)—wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2—C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: ApplicationFiled: September 12, 2023Publication date: January 25, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
-
Patent number: 11795236Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting positionType: GrantFiled: September 13, 2018Date of Patent: October 24, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Publication number: 20230186737Abstract: A customer is provided with a superior shopping experience while realizing hygiene management by using a transparent display medium with a point-of-sale (POS) terminal. Processing circuitry is configured to receive input relating to payment for a product from a first party, and display an image of an effect corresponding to the input relating to payment on the transparent display medium disposed so as to separate the first party from a second party who is purchasing the product.Type: ApplicationFiled: February 8, 2023Publication date: June 15, 2023Applicant: The Pokémon CompanyInventors: Masao YOSHIDA, Yasuhiko TERAMOTO, Akira KYOZUKA, Wakana KISHI
-
Patent number: 11633493Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LF-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: March 24, 2020Date of Patent: April 25, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Patent number: 11584800Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: August 19, 2020Date of Patent: February 21, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Patent number: 11261261Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: August 19, 2020Date of Patent: March 1, 2022Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Patent number: 11185594Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.Type: GrantFiled: April 6, 2015Date of Patent: November 30, 2021Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yusuke Ogitani, Yuki Abe
-
Patent number: 10973924Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: September 26, 2018Date of Patent: April 13, 2021Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Publication number: 20200385486Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: ApplicationFiled: August 19, 2020Publication date: December 10, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
-
Publication number: 20200282073Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LF-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: March 24, 2020Publication date: September 10, 2020Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi MASUDA, Hiroyuki NAITO, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Hideki MIYAZAKI, Yuji KASUYA, Koji MORITA, Yuki ABE, Yusuke OGITANI
-
Patent number: 10729782Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.Type: GrantFiled: November 22, 2017Date of Patent: August 4, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Takeshi Masuda, Hideki Miyazaki, Yuji Kasuya, Yuki Abe, Yusuke Ogitani
-
Publication number: 20200161167Abstract: A substrate holding member of the present disclosure includes a main body made of plate-shaped ceramics, and a coating film covering a surface of the main body, in which t1 is between 0.5 mm and 30 mm inclusive, t2 is between 3 ?m and 0.1 t1 inclusive, and an F value represented by Formula 1 is 1×1022 or more, where K1C denotes a fracture toughness, ?1 denotes a thermal expansion coefficient, t1 denotes a thickness, and E1 denotes a Young's modulus of the ceramics, ?2 denotes a thermal expansion coefficient, t2 denotes a thickness, E2 denotes a Young's modulus, and ? denotes a compressive strength of the coating film, and Sp denotes a safety factor of the substrate holding member. A semiconductor manufacturing device of the present disclosure includes the above-mentioned substrate holding member.Type: ApplicationFiled: July 30, 2018Publication date: May 21, 2020Inventors: Tetsuya INOUE, Masao YOSHIDA
-
Patent number: 10547053Abstract: A negative electrode active material for an electric device includes an alloy containing greater than or equal to 29% by mass of silicon and containing tin, carbon and inevitable impurities as a residue.Type: GrantFiled: November 5, 2012Date of Patent: January 28, 2020Assignee: Nissan Motor Co., Ltd.Inventors: Manabu Watanabe, Osamu Tanaka, Masao Yoshida
-
Patent number: 10516926Abstract: An object is to reduce weight load acting on a connecting member that connects a speaker unit and a bracket and keep the weight balance of the right and left of the speaker unit. A speaker unit mounting bracket is provided with a voltage converter, a base plate, and a cover. The cover covers the voltage converter and the base plate.Type: GrantFiled: April 24, 2018Date of Patent: December 24, 2019Assignee: YAMAHA CORPORATIONInventors: Masanori Kamihara, Masao Yoshida, Shotaro Kondo, Katsutoki Hanayama
-
Patent number: 10367198Abstract: A negative electrode active material for an electric device includes an alloy containing Si in a range of greater than or equal to 27% by mass and less than 100% by mass, Sn in a range of greater than 0% by mass and less than or equal to 73% by mass, V in a range of greater than 0% by mass and less than or equal to 73% by mass, and inevitable impurities as a residue. The negative electrode active material can be obtained with, for example, a multi DC magnetron sputtering apparatus by use of Si, Sn, and V as targets. An electric device using the negative electrode active material can achieve long cycle life and ensure a high capacity and cycle durability.Type: GrantFiled: March 9, 2012Date of Patent: July 30, 2019Assignee: NISSAN MOTOR CO., LTD.Inventors: Manabu Watanabe, Masao Yoshida, Osamu Tanaka
-
Publication number: 20190077880Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: ApplicationFiled: September 13, 2018Publication date: March 14, 2019Applicant: Daiichi Sankyo Company, LimitedInventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
-
Patent number: 10195288Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: GrantFiled: October 10, 2013Date of Patent: February 5, 2019Assignee: Daiichi Sankyo Company, LimitedInventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
-
Patent number: D897009Type: GrantFiled: June 26, 2019Date of Patent: September 22, 2020Assignee: Nissan Motor Co., Ltd.Inventors: Yusuke Hirata, Masao Yoshida, Shinya Momokawa